Epstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy

Abstract

Aplastic anemia is a rare blood disease characterized by the destruction of the hematopoietic stem cells (HSC) in the bone marrow that, in the majority of cases, is caused by an autoimmune reaction. Patients with aplastic anemia are treated with immunosuppressive drugs and some of them, especially younger individuals with a donor available, can be successfully treated with hematopoietic stem cell transplantation (HSCT). We report here a rare case of post-transplant lymphoproliferative disorder (PTLD) associated with Epstein–Barr virus (EBV) reactivation in a 30-year-old female patient who underwent allogeneic HSCT for severe aplastic anemia. The PTLD, which was diagnosed 230 days after transplantation, was localized exclusively in the central nervous system (specifically in the choroid plexus) and manifested with obvious signs of intracranial hypertension. After receiving three cycles of high dose methotrexate (HD-MTX) combined with rituximab, the patient achieved a complete clinical recovery with normalization of blood cell counts, no evidence of EBV reactivation, and no associated neurotoxicity.

Tumor Viruses and Their Associated Cancers: Remain on the Track with the Latest Advances

“…The rare condition of post-transplant lymphoproliferative disorder (PTLD) linked with EBV reactivation was detected in a case report on a female patient (30-year-old) who experienced allogeneic hematopoietic stem cell transplantation (HSCT) for acute aplastic anemia. A full clinical recovery with no signs of EBV reactivation and neurotoxicity was attained by treating the patient with three cycles of a high dose of methotrexate along with rituximab [11].…”